雌激素受体
雌激素受体α
生物
ERBB4公司
雌激素受体
癌症研究
交易激励
核受体
激素反应元件
雌激素
转录因子
信号转导
细胞生物学
内分泌学
乳腺癌
癌症
受体酪氨酸激酶
生物化学
基因
遗传学
作者
Yun Zhu,Lacey Sullivan,Sujit S. Nair,Christopher C. Williams,Arvind K. Pandey,Luis Marrero,Ratna K. Vadlamudi,Frank E. Jones
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2006-08-15
卷期号:66 (16): 7991-7998
被引量:151
标识
DOI:10.1158/0008-5472.can-05-4397
摘要
Although crosstalk between cell-surface and nuclear receptor signaling pathways has been implicated in the development and progression of endocrine-regulated cancers, evidence of direct coupling of these signaling pathways has remained elusive. Here we show that estrogen promotes an association between extranuclear estrogen receptor alpha (ER) and the epidermal growth factor receptor (EGFR) family member ERBB4. Ectopically expressed as well as endogenous ERBB4 interacts with and potentiates ER transactivation, indicating that the ERBB4/ER interaction is functional. Estrogen induces nuclear translocation of the proteolytic processed ERBB4 intracellular domain (4ICD) and nuclear translocation of 4ICD requires functional ligand-bound ER. The nuclear ER/4ICD complex is selectively recruited to estrogen-inducible gene promoters such as progesterone receptor (PgR) and stromal cell-derived factor 1 (SDF-1) but not to trefoil factor 1 precursor (pS2). Consistent with 4ICD-selective promoter binding, suppression of ERBB4 expression by interfering RNA shows that 4ICD coactivates ER transcription at the PgR and SDF-1 but not the pS2 promoter. Significantly, ERBB4 itself is an estrogen-inducible gene and the ERBB4 promoter harbors a consensus estrogen response element (ERE) half-site with overlapping activator protein-1 elements that bind ER and 4ICD in response to estrogen. Using a cell proliferation assay and a small interfering RNA approach, we show that ERBB4 expression is required for the growth-promoting action of estrogen in the T47D breast cancer cell line. Our results indicate that ERBB4 is a unique coregulator of ER, directly coupling extranuclear and nuclear estrogen actions in breast cancer. We propose that the contribution of an autocrine ERBB4/ER signaling pathway to tumor growth and therapeutic response should be considered when managing patients with ER-positive breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI